Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment

Acta Dermato-Venereologica

Volumn 88, Issue 2, 2008, Pages 185-186

  Kawakami, Yoshio ^a   Nakamura, Koichiro ^b   Nishibu, Akiko ^a   Yanagihori, Hirokatsu ^a   Kimura, Hideo ^a   Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB;

AGED; BLOOD EXAMINATION; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LETTER; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; NEOPLASMS, MULTIPLE PRIMARY; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SKIN NEOPLASMS;

EID: 41949088935     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0368     Document Type: Letter

References (13)

1. Grossman D, Leffell DJ. Squamous cell carcinoma. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's dermatology in general medicine, sixth edition. New York, McGraw Hill, 2004: p. 737-747.
2. Vassallo C, Passamonti F, Merante S, Ardigo M, Nolli G, Mangiacavalli S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukemia. Clin Exp Dermatol 2001; 26: 141-148.
3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
4. Roskoski R. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003; 309: 709-717.
5. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219.
6. Baker DE. Imatinib mesylate. Rev Gastroenterol Disord 2002; 2: 75-86.
7. Müller AM, Martens UM, Hofmann SC, Bruckner-Tuderman L, Mertelsmann R, Lübbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1-16.
8. Chu HR, Ongkeko WM, Diaz A, Altuna X, Aguilera J, Weisman RA, et al. Growth inhibition of head and neck squamous cell carcinoma by imatinib mesylate (Gleevec). Cancer Ther 2005; 3: 515-524.
9. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib. Strahlenther Onkol 2006; 182: 400-407.
10. Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006; 116: 1409-1416.
11. Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous cell carcinoma cells. J Cell Physiol 2005; 205: 218-227.
12. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H, et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003; 70: 231-234.
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine. N Engl J Med 2001; 344: 1031-1037.